Trials / Completed
CompletedNCT06975085
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 781 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- Female
- Age
- 39 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
Detailed description
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study seeks to understand the nature of the phenomenon of personalized cancer risk rejection in the context of mammography screening by testing hypotheses about why women reject their risk estimate and the influence of rejection on screening intentions. The Breast Cancer Risk Assessment Tool (BCRAT) will be used to asses participant's breast cancer risk. This model is designed to estimate breast cancer risk in women 35-84, and uses the following predictors: 1) age, 2) age at first menstrual period, 3) age at first live birth, 4) first-degree relatives with breast cancer, 5) previous breast biopsy with atypical hyperplasia, and 6) race/ethnicity. Participants will be required to complete a survey in which they receive their BCRAT model risk estimate and respond to that risk estimate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Presentation of a personal breast cancer risk estimate | Participants answer questions that are used to calculate their personal breast cancer risk using the Gail Model. This risk estimate is presented to participants using written text and an icon array. |
Timeline
- Start date
- 2025-04-16
- Primary completion
- 2025-04-30
- Completion
- 2025-04-30
- First posted
- 2025-05-16
- Last updated
- 2026-02-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06975085. Inclusion in this directory is not an endorsement.